Semaglutide, lipid-lowering drugs, and NAFLD

Lancet Diabetes Endocrinol. 2017 May;5(5):329-330. doi: 10.1016/S2213-8587(17)30109-2.

Authors

Niki Katsiki¹, Vasilios G Athyros¹, Asterios Karagiannis¹, Dimitri P Mikhailidis²

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
² Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London, London NW3 2QG, UK. Electronic address: mikhailidis@aol.com.

PMID: 28434490
DOI: 10.1016/S2213-8587(17)30109-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Glucagon-Like Peptides*
Humans
Hypoglycemic Agents
Lipids
Non-alcoholic Fatty Liver Disease*

Substances

Hypoglycemic Agents
Lipids
semaglutide
Glucagon-Like Peptides